Karyopharm Therapeutics Inc.

DB:25K Stock Report

Market Cap: €80.7m

Karyopharm Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:25K Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jan 25Sell€3,056Richard PaulsonIndividual4,055€0.75
04 Dec 24Sell€2,784Richard PaulsonIndividual3,620€0.77
05 Nov 24Sell€3,065Richard PaulsonIndividual3,675€0.83
04 Oct 24Sell€2,893Richard PaulsonIndividual3,607€0.80
04 Sep 24Sell€3,489Sohanya ChengIndividual5,356€0.65
04 Sep 24Sell€4,592Michael MasonIndividual7,050€0.65
04 Sep 24Sell€2,389Richard PaulsonIndividual3,667€0.65
04 Sep 24Sell€2,587Michael ManoIndividual3,971€0.65
06 Aug 24Sell€3,069Richard PaulsonIndividual3,608€0.85
30 Jul 24Sell€2,829Stuart PoultonIndividual2,883€0.98
05 Jul 24Sell€2,842Richard PaulsonIndividual3,616€0.79
07 Jun 24Sell€726,307Delphi Ventures, LLCCompany818,044€0.91
04 Jun 24Sell€809,356Delphi Ventures, LLCCompany906,178€0.92
04 Jun 24Sell€593Michael MasonIndividual652€0.91
04 Jun 24Sell€3,268Richard PaulsonIndividual3,592€0.91
06 May 24Sell€3,750Richard PaulsonIndividual3,576€1.05
22 Apr 24Sell€7,463Reshma RangwalaIndividual6,789€1.10
04 Apr 24Sell€4,231Richard PaulsonIndividual3,563€1.19
05 Mar 24Sell€4,274Richard PaulsonIndividual3,573€1.20
01 Mar 24Sell€108,441Richard PaulsonIndividual99,844€1.11
01 Mar 24Sell€29,266Sohanya ChengIndividual26,949€1.11
01 Mar 24Sell€22,307Michael ManoIndividual20,549€1.11
01 Mar 24Sell€24,450Stuart PoultonIndividual22,466€1.11
01 Mar 24Sell€23,548Reshma RangwalaIndividual21,636€1.11
01 Mar 24Sell€36,752Michael MasonIndividual33,849€1.11
27 Feb 24Sell€3,105Michael MasonIndividual2,545€1.22
15 Feb 24Sell€7,235Stuart PoultonIndividual5,847€1.30
06 Feb 24Sell€6,208Michael MasonIndividual4,205€1.48
06 Feb 24Sell€5,923Richard PaulsonIndividual4,012€1.48

Insider Trading Volume

Insider Buying: 25K insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 25K?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders772,2310.612%
Private Companies6,872,0275.45%
Hedge Funds9,744,8857.72%
General Public46,582,87236.9%
Institutions62,218,72949.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 56.9% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.72%
Highbridge Capital Management, LLC
9,744,885€6.2m0%0.15%
6.07%
The Vanguard Group, Inc.
7,654,482€4.9m0%no data
5.45%
J. Wood Capital Advisors LLC
6,872,027€4.4m0%no data
4.4%
Eversept Partners, L.P.
5,547,880€3.5m11.2%0.31%
4.04%
Palo Alto Investors LP
5,102,193€3.3m0%0.48%
3.76%
Avidity Partners Management, L.P.
4,741,060€3.0m135%0.18%
3.42%
Adage Capital Management, L.P.
4,319,842€2.8m0%no data
2.88%
BlackRock, Inc.
3,638,378€2.3m-12.7%no data
2.46%
Citadel Advisors LLC
3,103,669€2.0m0.07%no data
1.65%
Marshall Wace LLP
2,082,226€1.3m-19.3%no data
1.57%
BNP Paribas Arbitrage Sa, Asset Management Arm
1,982,354€1.3m-12.8%no data
1.41%
GSA Capital Partners LLP
1,775,700€1.1m80.6%0.09%
1.19%
C WorldWide Asset Management Fondsmaeglerselskab A/S
1,500,000€959.5k0%0.01%
1.1%
JPMorgan Chase & Co, Brokerage and Securities Investments
1,385,724€886.4k8.61%no data
1.07%
Geode Capital Management, LLC
1,355,392€867.0k3.34%no data
1.06%
Goldman Sachs Group, Investment Banking and Securities Investments
1,336,715€855.1k-39.4%no data
1.01%
Deutsche Asset & Wealth Management
1,268,777€811.6k0%no data
0.99%
Millennium Management LLC
1,255,264€803.0k-40%no data
0.98%
Renaissance Technologies LLC
1,241,407€794.1k64.2%no data
0.95%
Kennedy Capital Management LLC
1,204,009€770.2k0.6%0.02%
0.95%
UBS O'Connor LLC
1,196,174€765.2k8.51%0.07%
0.89%
Alphacentric Advisors LLC
1,125,000€719.6k0%0.53%
0.83%
D. E. Shaw & Co., L.P.
1,047,396€670.0k24.1%no data
0.59%
Altium Capital Management LP
740,000€473.4k0%0.16%
0.46%
Point72 Asset Management, L.P.
578,682€370.2k-24.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 00:22
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Peter LawsonBarclays
Ying HuangBofA Global Research